GlassScriptPhysician profile
Arthur E Farkash
NPI 1871578807
$4,047.44
in general payments reported to CMS, 2019-2025
45 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.59 · 2020: $52.71 · 2021: $509 · 2022: $1,029 · 2023: $1,288 · 2024: $536 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.14 |
| Education | $141.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,370.88 | 2021-2025 | |
| Pfizer INC. | $334.27 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $255.26 | 2019-2023 | Qelbree |
| Neurocrine Biosciences, INC. | $160.94 | 2022-2023 | Ongentys, Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $139.62 | 2022 | |
| Neurelis, INC. | $134.20 | 2023 | Valtoco |
| Lilly USA, LLC | $127.53 | 2021-2025 | Omvoh, Amyvid |
| Lundbeck LLC | $120.43 | 2021-2023 | Vyepti, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $118.21 | 2021-2023 | Entyvio, Gammagard Liquid |
| Amgen INC. | $113.42 | 2021-2022 | |
| Ucb, INC. | $94.14 | 2022-2023 | Briviact |
| Tris Pharma INC | $91.14 | 2022-2024 | Dyanavel Xr |
| Biohaven Pharmaceuticals, INC. | $74.50 | 2021 | |
| Alexion Pharmaceuticals, INC. | $69.75 | 2021-2022 | |
| Allergan, INC. | $67.24 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Farkash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.